NASDAQ:DCOY Decoy Therapeutics (DCOY) Stock Price, News & Analysis $4.97 +0.46 (+10.07%) As of 10:19 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About Decoy Therapeutics Stock (NASDAQ:DCOY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Decoy Therapeutics alerts:Sign Up Key Stats Today's Range$4.50▼$4.6450-Day Range$4.52▼$8.6152-Week Range$4.50▼$415.80Volume751 shsAverage Volume131,860 shsMarket Capitalization$2.64 millionP/E RatioN/ADividend YieldN/APrice Target$30.00Consensus RatingHold Company Overview Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas. Read More Decoy Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreDCOY MarketRank™: Decoy Therapeutics scored higher than 54% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingDecoy Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialDecoy Therapeutics has a consensus price target of $30.00, representing about 563.7% upside from its current price of $4.52.Amount of Analyst CoverageDecoy Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Decoy Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Decoy Therapeutics are expected to decrease in the coming year, from ($12.97) to ($19.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Decoy Therapeutics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Decoy Therapeutics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDecoy Therapeutics has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.13% of the float of Decoy Therapeutics has been sold short.Short Interest Ratio / Days to CoverDecoy Therapeutics has a short interest ratio ("days to cover") of 0.85, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Decoy Therapeutics has recently decreased by 51.49%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDecoy Therapeutics does not currently pay a dividend.Dividend GrowthDecoy Therapeutics does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment1.06 News SentimentDecoy Therapeutics has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Manufacturing companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Decoy Therapeutics this week, compared to 3 articles on an average week.Search Interest1 people have searched for DCOY on MarketBeat in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Decoy Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders0.30% of the stock of Decoy Therapeutics is held by insiders.Percentage Held by Institutions11.88% of the stock of Decoy Therapeutics is held by institutions.Read more about Decoy Therapeutics' insider trading history. Receive DCOY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Decoy Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DCOY Stock News HeadlinesDecoy Therapeutics (NASDAQ:DCOY) Trading Up 2.9% - Here's WhyMay 7, 2026 | americanbankingnews.comDecoy Therapeutics to Present at Two Peptide Therapeutics Conferences in BostonApril 27, 2026 | prnewswire.com$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s known for playing his cards “close to the vest”… Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…May 15 at 1:00 AM | Paradigm Press (Ad)Decoy Therapeutics Inc. (DCOY) Discusses Corporate Overview and Pipeline Progress in Antiviral Drug Development TranscriptApril 9, 2026 | seekingalpha.comDecoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral PipelineApril 9, 2026 | prnewswire.comDecoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026April 6, 2026 | prnewswire.comDecoy Therapeutics Regains Nasdaq Compliance After Reverse SplitApril 2, 2026 | tipranks.comDecoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementApril 2, 2026 | prnewswire.comSee More Headlines DCOY Stock Analysis - Frequently Asked Questions How have DCOY shares performed this year? Decoy Therapeutics' stock was trading at $9.36 at the beginning of the year. Since then, DCOY stock has decreased by 51.7% and is now trading at $4.52. How were Decoy Therapeutics' earnings last quarter? Decoy Therapeutics (NASDAQ:DCOY) issued its quarterly earnings results on Friday, May, 8th. The company reported ($4.18) earnings per share (EPS) for the quarter. When did Decoy Therapeutics' stock split? Decoy Therapeutics's stock reverse split on the morning of Monday, March 9th 2026.The 1-12 reverse split was announced on Thursday, March 5th 2026. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 6th 2026. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Decoy Therapeutics? Shares of DCOY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/08/2026Today5/15/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 DCOY's financial health is in the Red zone, according to TradeSmith. DCOY has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorManufacturing Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DCOY CIK1615219 WebN/A Phone(346) 772-0346FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for Decoy Therapeutics$30.00 High Price Target$30.00 Low Price Target$30.00 Potential Upside/Downside+503.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($106.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.52 million Net MarginsN/A Pretax MarginN/A Return on Equity-395.42% Return on Assets-193.30% Debt Debt-to-Equity RatioN/A Current Ratio1.84 Quick Ratio2.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.29 per share Price / Book0.68Miscellaneous Outstanding Shares530,000Free Float530,000Market Cap$2.64 million OptionableN/A Beta0.38 The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:DCOY) was last updated on 5/15/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Decoy Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Decoy Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
